These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29464355)

  • 1. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.
    Nakaigawa N; Kondo K; Tateishi U; Minamimoto R; Kaneta T; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Kubota Y; Inoue T; Yao M
    BMC Cancer; 2016 Feb; 16():67. PubMed ID: 26857818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma.
    Pankowska V; Malkowski B; Wedrowski M; Wedrowska E; Roszkowski K
    Clin Exp Med; 2019 Feb; 19(1):143-148. PubMed ID: 30488140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early assessment with
    Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
    BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
    Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance and prognostic value of preoperative
    Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
    Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
    Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
    PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma.
    Gulturk I; Yilmaz M; Tacar SY; Tural D
    Q J Nucl Med Mol Imaging; 2023 Sep; 67(3):223-229. PubMed ID: 34881845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
    Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of basal 18F-FDG PET / CT maximum standardized uptake value in patients with metastatic renal cell carcinoma who were treated with sunitinib.
    Aytekin A; Aldemir MN; Sakin A; Telci U; Esen R
    J BUON; 2020; 25(5):2490-2495. PubMed ID: 33277873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
    Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
    Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
    Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
    Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
    Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
    Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.